Long-term treatment with testosterone undecanoate was associated with reduced cardiovascular morbidity and mortality in patients with hypogonadism and type 2 diabetes.
Genetically low 25-hydroxyvitamin D levels are associated with lower testosterone levels.
In a subanalysis, researchers discovered that testosterone deficiency was common in men with a sustained virologic response after being treated for hepatitis C.
Testosterone replacement therapy prevents further bone loss at the lumbar and femoral levels in patients with congenital hypogonadotropic hypogonadism, but it does not reliably elevate bone mineral density out of the osteopenic/osteoporotic range.
The Food and Drug Administration (FDA) has approved Jatenzo (testosterone undecanoate; Clarus Therapeutics) capsules for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: congenital or acquired primary hypogonadism or hypogonadotropic hypogonadism.
Men with prediabetes, hypogonadism achieved normal glucose regulation with TTh
Despite research suggesting that there may be increased cardiovascular risk from off-label prescription testosterone use, usage in men with coronary artery disease remains higher than in men without coronary artery disease.
Xyosted carries a Boxed Warning regarding blood pressure increases that may potentially increase the risk for major adverse cardiovascular events.
Investigators examine total testosterone, free testosterone, and sex hormone binding globulin levels in pregnant women in the third trimester with PCOS.
This finding suggests that clinicians should monitor anxiety among individuals with testosterone deficiency and XXY.
Investigators examine the onset of puberty and testicular function in prepubertal boys treated with oxandrolone.